Ciforadenant
- Generic Name
- Ciforadenant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N7O3
- CAS Number
- 1202402-40-1
- Unique Ingredient Identifier
- 8KFO2187CP
- Background
Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).
- Associated Conditions
- -
- Associated Therapies
- -
Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+
Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant
New data presented at SITC 39th Annual Meeting highlights ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms.
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to ...
The article discusses the importance of enabling JavaScript for optimal app performance.
Corvus Pharmaceuticals Announces New Data Highlighting
Corvus Pharmaceuticals presents data on ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms. The study, led by Dr. Lawrence Fong, showed ciforadenant's efficacy in reducing immunosuppression and enhancing anti-PD1 therapy sensitivity in a murine model, consistent with clinical trial data.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath